4 months ago
ZVRA
AnalystsEddie HickmanEddie Hickman's Stock Forecasts
AnalystsEddie Hickman
Sectors:
Industries:
Analyst Ranking
Top 28%
#1393 out of 4929 analysts
Average Return
+18.01%
Win Rate
54%7 out of 13
Risk vs Reward
Poor
Good
Eddie Hickman's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Iveric Bio IncISEE | +167.40% | $14.94 | $39.95 | 2022-09-07 - 2023-07-10 | Strong Buy |
Tarsus Pharmaceuticals IncTARS | +85.16% | $16.98 | $31.44 | 2023-09-11 - 2024-09-10 | Strong Buy |
Tarsus Pharmaceuticals IncTARS | +67.37% | $18.51 | $30.98 | 2023-06-16 - 2024-06-14 | Strong Buy |
Tarsus Pharmaceuticals IncTARS | +57.10% | $16.83 | $26.44 | 2023-08-14 - 2024-08-13 | Strong Buy |
Gh Research PLCGHRS | +37.09% | $10.88 | $14.92 | 2025-03-13 - 2025-07-03 | Strong Buy |
Eddie Hickman Analyst Color
Get additional color on Eddie Hickman's coverage of popular stocks
Eddie Hickman's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Tarsus Pharmaceuticals IncTARS | 5 | Strong Buy | $84.00 | +104.13% | Maintains | 2 months ago |
Promis Neurosciences IncPMN | 1 | Strong Buy | $6.00 | +1,295.35% | Reiterates | 3 months ago |
Zevra Therapeutics IncZVRA | 1 | Strong Buy | $22.00 | +125.87% | Maintains | 4 months ago |
Gh Research PLCGHRS | 1 | Strong Buy | $32.00 | +114.55% | Initiates Coverage On | 4 months ago |
Cybin IncCYBN | 1 | Strong Buy | $35.00 | +340.81% | Initiates Coverage On | 4 months ago |
Outlook Therapeutics IncOTLK | 3 | Strong Buy | $12.00 | +574.16% | Reiterates | 6 months ago |
Iveric Bio IncISEE | 1 | Strong Buy | $35.00 | N/A | Maintains | 3 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.